Adam Maeder

Stock Analyst at Piper Sandler

(0)
# 3572
Out of 5,293 analysts
131
Total ratings
50.77%
Success rate
-0.60%
Average return
20 Stocks
Name Action Price Target Current % Upside Ratings Updated
RBOT Vicarious Surgical
Maintains: Neutral
11 9
6.46 31.58% 7 Mar 18, 2025
EW Edwards Lifesciences
Maintains: Neutral
70 73
71.83 1.63% 13 Feb 12, 2025
INSP Inspire Medical Syst...
Maintains: Overweight
260 233
157.79 47.66% 14 Feb 10, 2025
NVRO Nevro
Upgrades: Neutral
6 6
5.84 0.17% 16 Feb 7, 2025
RMD ResMed
Maintains: Neutral
252 260
222.15 17.04% 2 Jan 31, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
538 670
496 35.08% 18 Jan 24, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
52 80
n/a n/a 7 Jan 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
131 133
131.59 1.07% 2 Oct 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
5 5
2.51 79.28% 3 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
20 21
12.87 63.17% 2 May 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
18 20
n/a n/a 6 May 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
290 360
n/a n/a 10 Apr 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
7 8
3.78 111.64% 1 Mar 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
15 20
6.85 191.97% 8 Mar 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
75 71
n/a n/a 8 Jan 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
25 30
13.6 120.59% 2 May 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
6 5
1.72 190.7% 2 Mar 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
10 18
2.48 625.81% 2 Jan 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
104 99
39.03 153.65% 3 May 5, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 11
n/a n/a 5 Jun 14, 2021